Clinical Trials
272 trialsNCT05650242 2024-11-08
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
Shandong Boan Biotechnology Co., Ltd
Phase 1 Unknown
NCT06410703 2024-10-31
CAN1012 Combined With PD-1 in Patients With Solid Tumors
Canwell Biotech Limited
Phase 1/2 Unknown
NCT06196762 2024-10-10
Phase I of XKH002 Injection in Patients
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 1 Unknown
NCT06533605 2024-08-01
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 1 Unknown
NCT06199908 2024-07-26
AMT-562 in Patients With Selected Advanced Solid Tumors
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT06256055 2024-07-24
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Phase 1 Unknown
NCT06433726 2024-05-30
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
Chengdu Baiyu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04092673 2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2 Unknown
NCT05751356 2024-05-14
TR128 in Patients With Advanced Solid Tumors
Tarapeutics Science Inc.
Phase 1 Unknown
NCT05804526 2024-04-30
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
RemeGen Co., Ltd.
Phase 1/2 Unknown
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Unknown
NCT05700084 2024-04-19
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT05087745 2024-04-17
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Unknown
NCT05483530 2024-04-16
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT06368960 2024-04-16
BM201-1001
InnoBM Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT06348290 2024-04-04
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
Jemincare
Phase 1 Unknown
NCT06247657 2024-04-03
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
Shanghai Best-Link Bioscience, LLC
Phase 1 Unknown
NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT05394168 2024-04-01
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05037149 2024-03-18
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Sirnaomics
Phase 1 Unknown
NCT05798026 2024-03-13
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Eutilex
Phase 1 Unknown
NCT06139536 2024-03-13
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Unknown
NCT05103046 2024-03-12
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
1200 Pharma, LLC
Phase 1 Unknown
NCT06237413 2024-03-06
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT05836623 2024-02-28
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Crescendo Biologics Ltd.
Phase 1 Unknown
NCT05971862 2024-02-21
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors
Oscotec Inc.
Phase 1 Unknown
NCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT04984668 2024-02-09
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Suzhou Kintor Pharmaceutical Inc,
Phase 1/2 Unknown
NCT03863145 2024-02-07
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
Cosmo Pharmaceuticals NV
Phase EARLY_PHASE1 Unknown
NCT05367232 2024-02-07
A Study of ICP-033 in Patients With Advanced Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1 Unknown
NCT06232863 2024-02-02
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Zhuhai Beihai Biotech Co., Ltd
Phase 1 Unknown
NCT06237400 2024-02-01
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT05278975 2024-01-26
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Phase 1/2 Unknown
NCT05388487 2024-01-16
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
HighField Biopharmaceuticals Corporation
Phase 1 Unknown
NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT06001684 2024-01-03
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1 Unknown
NCT05164458 2023-12-28
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT04739293 2023-12-07
Study of ON 123300 in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Unknown
NCT05490264 2023-12-07
[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors
SmartNuclide Biopharma
Phase EARLY_PHASE1 Unknown
NCT06154343 2023-12-04
A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT05886868 2023-11-29
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors
Shanghai Best-Link Bioscience, LLC
Phase 1 Unknown
NCT04190823 2023-11-27
A Study of RC98 in Subjects With Advanced Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1 Unknown
NCT04894825 2023-11-27
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 1 Unknown
NCT05101265 2023-11-27
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
PharmaMar
Phase 1 Unknown
NCT04839991 2023-11-18
POTENTIA
Crescendo Biologics Ltd.
Phase 1 Unknown
NCT04294576 2023-11-09
FIH
BJ Bioscience, Inc.
Phase 1 Unknown
NCT05681000 2023-11-09
Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT06116240 2023-11-03
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT04156347 2023-10-31
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
Targeted Therapy Technologies, LLC
Phase 1 Unknown
NCT06056323 2023-10-23
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown